Last edition
News about "Pegfilgrastim Biosimilar"
Biocon's Pegfilgrastim Biosimilar Gets Japan MHLW Approval
Biocon’s pegfilgrastim biosimilar receives Japan MHLW marketing approval, strengthening the company’s biosimilar portfolio and expanding access in Japan.
Pegfilgrastim Biosimilar | 25/08/2026 | By News Bureau
US FDA Approves Accord BioPharma's ENNUMO Pegfilgrastim Biosimilar
The US Food and Drug Administration (FDA) has approved Accord BioPharma’s ENNUMO (pegfilgrastim-pccg), expanding its US biosimilar portfolio and strengthening access to G-CSF therapies for cancer patients.
Pegfilgrastim Biosimilar | 10/07/2026 | By News Bureau | 119
Lupin Secures US FDA Approval for Pegfilgrastim Biosimilar Armlupeg
Lupin has received approval from the U.S. Food and Drug Administration (FDA) for its biosimilar Armlupeg (pegfilgrastim-unne), marking an important milestone in the company’s biologics journey. Armlupeg is a biosimilar to Neulasta (pegfilgrastim), a widely used therapy that helps reduce infection risk in cancer patients undergoing chemotherapy.
Pegfilgrastim Biosimilar | 01/12/2025 | By Darshana | 270
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy